Cargando…

Intervention of Shugan Xiaozhi Decoction on Nonalcoholic Fatty Liver Disease via Mediating Gut-Liver Axis

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with an increasing incidence rate but few therapies. Shugan Xiaozhi decoction (SX) has demonstrated beneficial effects in treating NAFLD with an unclear mechanism. This study was aimed at investigating the therapeutic mechanism of S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Huili, Feng, Lian, Xu, Linyi, Jiang, Dansheng, Zhai, Fenfen, Tong, Guangdong, Xing, Yufeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276511/ https://www.ncbi.nlm.nih.gov/pubmed/35837380 http://dx.doi.org/10.1155/2022/4801695

Ejemplares similares

Investigation of the potential mechanism of the Shugan Xiaozhi decoction for the treatment of nonalcoholic fatty liver disease based on network pharmacology, molecular docking and molecular dynamics simulation
por: Yang, Rong, et al.
Publicado: (2022)

Shugan Xiaozhi Decoction Attenuates Nonalcoholic Steatohepatitis by Enhancing PPARα and L-FABP Expressions in High-Fat-Fed Rats
por: Xing, Yu-feng, et al.
Publicado: (2016)

Xiaozhi decoction reduced posthemorrhoidectomy pain and analgesic medication consumption: a prospective study
por: Shen, Jianbin, et al.
Publicado: (2017)

Mechanistic Research into the Effects of the Jianpi Xiaozhi Formula on Liver Injury in Diabetic Rats
por: Yuanyuan, Zhang, et al.
Publicado: (2022)

Bile Acid Receptors and the Gut–Liver Axis in Nonalcoholic Fatty Liver Disease
por: Xue, Rui, et al.
Publicado: (2021)

Efficacy and safety of acetyl-CoA carboxylase (ACC) inhibitors in the treatment of nonalcoholic steatohepatitis (NASH): A protocol for systematic review
por: Xu, Liubin, et al.
Publicado: (2022)

Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease
por: Xu, Yu, et al.
Publicado: (2021)

Danshao Shugan Granule therapy for non-alcoholic fatty liver disease
por: Wang, Hui, et al.
Publicado: (2022)

Wendan decoction in the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis
por: Zhang, Yufeng, et al.
Publicado: (2022)

Volatile Oil of Amomum villosum Inhibits Nonalcoholic Fatty Liver Disease via the Gut-Liver Axis
por: Lu, Shanhong, et al.
Publicado: (2018)

The role of microbiome in the pathogenesis of oral-gut-liver axis between periodontitis and nonalcoholic fatty liver disease
por: Chen, Tsung-Po, et al.
Publicado: (2023)

Evaluation of the Mechanism of Modified Lingguizhugan Decoction in the Treatment of Nonalcoholic Fatty Liver Disease
por: Yang, Fuyuan, et al.
Publicado: (2022)

The Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: Association of Intestinal Permeability with Disease Severity and Treatment Outcomes
por: Zhuang, Yu-Pei, et al.
Publicado: (2022)

Bifidobacterium-derived short-chain fatty acids and indole compounds attenuate nonalcoholic fatty liver disease by modulating gut-liver axis
por: Yoon, Sang Jun, et al.
Publicado: (2023)

Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease
por: Boursier, Jerome, et al.
Publicado: (2015)

The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease
por: Roychowdhury, Sanjoy, et al.
Publicado: (2018)

Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease
por: Sharpton, Suzanne R., et al.
Publicado: (2018)

Erratum to “Evaluation of the Mechanism of Modified Lingguizhugan Decoction in the Treatment of Nonalcoholic Fatty Liver Disease”
por: Yang, Fuyuan, et al.
Publicado: (2022)

New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease
por: Bertran, Laia, et al.
Publicado: (2022)

Zhuyu Pill Alleviates Nonalcoholic Fatty Liver Disease by Regulating Bile Acid Metabolism through the Gut–Liver Axis
por: Xu, Lu, et al.
Publicado: (2023)

Periodontal disease–related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral‐liver axis
por: Kuraji, Ryutaro, et al.
Publicado: (2021)

Gegen Qinlian Decoction Ameliorates Nonalcoholic Fatty Liver Disease in Rats via Oxidative Stress, Inflammation, and the NLRP3 Signal Axis
por: Ying, Yuqi, et al.
Publicado: (2021)

Butyrate-Producing Probiotics Reduce Nonalcoholic Fatty Liver Disease Progression in Rats: New Insight into the Probiotics for the Gut-Liver Axis
por: Endo, Hitoshi, et al.
Publicado: (2013)

Involvement of the liver-gut peripheral neural axis in nonalcoholic fatty liver disease pathologies via hepatic HTR2A
por: Owaki, Takashi, et al.
Publicado: (2022)

Effectiveness and safety of Shugan Jianpi (SGJP) formula in the treatment of nonalcoholic steatohepatitis (NASH): A protocol for systematic review and meta-analysis of randomized controlled trials
por: Chen, Mingtai, et al.
Publicado: (2021)

Retraction: Nonalcoholic fatty liver disease, diet and gut microbiota
por: Finelli, Carmine, et al.
Publicado: (2017)

Gut Microbiota and Risk of Persistent Nonalcoholic Fatty Liver Diseases
por: Kim, Han-Na, et al.
Publicado: (2019)

Metagenome of Gut Microbiota of Children With Nonalcoholic Fatty Liver Disease
por: Zhao, Yuzhen, et al.
Publicado: (2019)

Gut microbiota profile in patients with nonalcoholic fatty liver disease and presumed nonalcoholic steatohepatitis
por: Mohammadi, Zahra, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy
por: Fianchi, Francesca, et al.
Publicado: (2021)

Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease
por: Wang, Yun-liang, et al.
Publicado: (2015)

Effects of Qutanhuoxue Decoction on AQP7 and AQP9 Expression in Nonalcoholic Fatty Liver Model Rats
por: Zheng, Ding, et al.
Publicado: (2019)

Sijunzi, Lizhong, and Fuzilizhong Decoction Alleviate Nonalcoholic Fatty Liver Disease through Activation of PPAR Pathway
por: Yang, Jiayao, et al.
Publicado: (2020)

Xuefu Zhuyu decoction for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis
por: Liu, Jiaxin, et al.
Publicado: (2021)

Xiaochaihu decoction for nonalcoholic fatty liver disease: A protocol for a systematic review and meta-analysis
por: Zhu, Wenyu, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease
por: Bebawi, Emmanuel, et al.
Publicado: (2023)

Characterization of gut microbiome composition in Iranian patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Abdollahiyan, Sara, et al.
Publicado: (2023)

Jian-Gan-Xiao-Zhi Decoction Alleviates Inflammatory Response in Nonalcoholic Fatty Liver Disease Model Rats through Modulating Gut Microbiota
por: Liao, Jiabao, et al.
Publicado: (2021)

Efficacy and safety of Shugan Jieyu Decoction in the treatment of coronary heart disease complicated with depression
por: Li, Zhenzhen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hs7o53ta7rt3tk0o9o552e09ab